Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 10/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348837 | 0.86 | KMT2A (0.47) | KMT2AKDM1AFABP7FABP5POLB | |
| Hydrochloric Acid SCHEMBL2348833 | 0.85 | KMT2A (0.46) | KMT2AKDM1AFABP7FABP5POLB | |
| SCHEMBL2382024 | 0.83 | KMT2A (0.47) | KMT2AFABP7FABP5POLBTSHR | |
| SCHEMBL16004761 | 0.83 | POLB (0.46) | KMT2AFABP7FABP5POLBTSHR | |
| SCHEMBL22397770 | 0.83 | POLB (0.52) | KMT2AFABP7FABP5POLBTSHR | |
| SCHEMBL13327274 | 0.83 | POLB (0.52) | KMT2AFABP7FABP5POLBTSHR | |
| Hydrochloric Acid SCHEMBL2345547 | 0.82 | KMT2A (0.46) | KMT2AFABP7FABP5POLBTSHR | |
| SCHEMBL28864147 | 0.81 | EPHX2 (0.44) | KMT2AKDM1AFABP7FABP5POLB | |
| SCHEMBL27143217 | 0.81 | KMT2A (0.43) | KMT2AFABP7FABP5POLBTSHR | |
| SCHEMBL8222797 | 0.80 | TSHR (0.50) | KMT2AFABP7FABP5POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051329-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210171523-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200071329-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-10377755-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190040062-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377755-B2 | BCL-2 inhibitors | BCL2L1, BCL2, BCL2A1 | KMT2A 927/4885KDM1A 673/4885MAOA 2813/4885 |
| US-20200071329-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | KMT2A 927/4885KDM1A 673/4885MAOA 2813/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | KMT2A 675/4885KDM1A 557/4885MAOA 4092/4885 |
| US-20210171523-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | KMT2A 927/4885KDM1A 673/4885MAOA 2813/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | KMT2A 675/4885KDM1A 557/4885MAOA 4092/4885 |
| US-20250051329-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | KMT2A 927/4885KDM1A 673/4885MAOA 2813/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | KMT2A 630/4885KDM1A 500/4885MAOA 4266/4885 |
| US-20190040062-A1 | BCL-2 INHIBITORS | BCL2L1, BCL2, BCL2A1 | KMT2A 927/4885KDM1A 673/4885MAOA 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.